Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR1B | P28222 | 12/20 | 1.00 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.51 |
| ▸ | F10 | P00742 | 5/20 | 0.50 |
| ▸ | NPC1 | O15118 | 1/20 | 0.49 |
| ▸ | RAB9A | P51151 | 1/20 | 0.49 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14263965 | 0.97 | HTR1B (1.00) | HTR1BKCNH2NPC1RAB9AL3MBTL1 | |
| SCHEMBL14263970 | 0.86 | HTR1B (1.00) | HTR1BNPC1RAB9A | |
| SCHEMBL14263964 | 0.85 | HTR1B (0.79) | HTR1BNPC1RAB9AL3MBTL1 | |
| SCHEMBL6995168 | 0.84 | HTR1B (0.72) | HTR1BKCNH2F10NPC1RAB9A | |
| SCHEMBL5994036 | 0.82 | HTR1B (1.00) | HTR1BL3MBTL1 | |
| SCHEMBL14263969 | 0.82 | HTR1B (1.00) | HTR1BL3MBTL1 | |
| SCHEMBL14437495 | 0.81 | HTR1B (0.91) | HTR1BNPC1RAB9A | |
| SCHEMBL14437527 | 0.80 | HTR1B (0.74) | HTR1BF10NPC1RAB9AL3MBTL1 | |
| SCHEMBL14263877 | 0.80 | HTR1B (0.70) | HTR1BKCNH2NPC1RAB9AL3MBTL1 | |
| SCHEMBL4989817 | 0.80 | HTR1B (0.65) | HTR1BF10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2020183011-A1 | HTR1D INHIBITORS AND USES THEREOF IN THE TREATMENT OF CANCER | INSTITUT CURIE (FR) | 2020-09-17 | — | — | WO | disclosed |
| US-20080076759-A1 | Therapeutic Heterocyclic Compounds 507 | ASTRAZENECA AB (SE) | 2008-03-27 | — | — | US | disclosed |
| US-20080076759-A1 | Therapeutic Heterocyclic Compounds 507 | ASTRAZENECA AB (SE) | 2008-03-27 | — | — | US | disclosed |
| US-7285662-B2 | Therapeutic heterocyclic compounds | ASTRAZENECA AB (SE) | 2007-10-23 | — | — | US | disclosed |
| US-7285662-B2 | Therapeutic heterocyclic compounds | ASTRAZENECA AB (SE) | 2007-10-23 | — | — | US | disclosed |
| US-7285662-B2 | Therapeutic heterocyclic compounds | ASTRAZENECA AB (SE) | 2007-10-23 | — | — | US | disclosed |
| US-7026314-B2 | Psychological disorders, antidepressants, anxiolytic agents, eating disorders; serotonin receptors antagonist | ASTRAZENECA AB (SE) | 2006-04-11 | — | — | US | disclosed |
| EP-1353914-A2 | THERAPEUTIC CHROMONE COMPOUNDS | AstraZeneca AB (SE) | 2003-10-22 | — | — | EP | disclosed |
| EP-1353915-A2 | THERAPEUTIC CHROMAN COMPOUNDS | AstraZeneca AB (SE) | 2003-10-22 | — | — | EP | disclosed |
| EP-1353913-A2 | THERAPEUTIC HETEROCYCLIC COMPOUNDS | AstraZeneca AB (SE) | 2003-10-22 | — | — | EP | disclosed |
| WO-2002055013-A2 | THERAPEUTIC CHROMONE COMPOUNDS | ASTRAZENECA AB (SE) | 2002-07-18 | — | — | WO | disclosed |
| WO-2002055012-A2 | THERAPEUTIC HETEROCYCLIC COMPOUNDS | ASTRAZENECA AB (SE) | 2002-07-18 | — | — | WO | disclosed |
| WO-2002055014-A2 | THERAPEUTIC CHROMAN COMPOUNDS | ASTRAZENECA AB (SE) | 2002-07-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080076759-A1 | Therapeutic Heterocyclic Compounds 507 | HTR1A, HTR1B, HTR1D | HTR1B 2/4885KCNH2 2598/4885F10 830/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.